Melbourne (Australia) and Indianapolis, IN (U.S.A.) | 4 February 2025

Telix currently generates most of its revenue from U.S. sales of Illuccix®1. Because of the “just-in-time” nature of radiopharmaceutical products, such products are generally manufactured in close proximity to the customer. This will continue to be the case for new products that are anticipated to be launched in 2025. 

Due to Telix’s extensive U.S.-based manufacturing and distribution infrastructure and partner networks, Telix does not expect any material impact on its business as the result of current international trade tariffs levied by the U.S. Government.   

  1. Telix’s lead prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA), by the Australian Therapeutic Goods Administration (TGA), and by Health Canada. Telix has received a positive decision on its Marketing Authorization Application (MAA) for Illuccix submitted in Europe. ↩︎